Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Finranks

Компания

  • О нас

Контакты

  • [email protected]

Мы в соцсетях

  • Instagram
  • Telegram
  • LinkedIn

Все права защищены.

Условия использования
  • Главная
  • Рынки
  • Скринер
  • Новости
  • О нас
  1. Home
  3. OVID
O

Ovid Therapeutics Inc. (OVID)

2.30

0.00 (0.00%)

  • Обзор
  • Новости
  • График
  • Финансы
  • Дивиденды
  • Прогноз
  • Владельцы
  • Профиль
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding
20.03.2026

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal onset seizures after soticlestat's failure. Recent Phase 1 data show OV329 lacks the eye toxicity seen with vigabatrin, supporting its differentiated safety profile. Management secured $60M PIPE financing, extending the cash runway into 2029, but a $385.7M modeled funding gap implies 11% annual dilution over six years.

Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript
18.03.2026

Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript

Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript

Here's Why Ovid Therapeutics Stock Popped Higher Today
18.03.2026

Here's Why Ovid Therapeutics Stock Popped Higher Today

OV329 may be safer and more potent than existing treatments. A $60M private placement will fund further development.

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally
18.03.2026

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally

Ovid Therapeutics reported favorable topline safety and tolerability findings from a 7 mg dose cohort of OV329 for drug-resistant epilepsies.

Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
18.03.2026

Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates

Ovid Therapeutics (OVID) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.13 per share a year ago.

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
18.03.2026

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today provided pipeline progress and business updates, including financial results for the fourth quarter and full year ended December 31, 2025. The Company reported favorable topline safety, tolerability and pharmacokinetics (PK) findings from the 7 mg dose cohort of OV329, its next generation GABA-aminotransferase (GABA-AT) inhibitor. Additionally the Company announced it will add complementary development programs for OV329, expanding into tuberous sclerosis complex (TSC) seizures and infantile spasms (IS) which is funded by a private placement financing expected to result in gross proceeds of $60.0 million, before deducting placement agent fees and offering expenses.

Ovid Therapeutics Announces Pricing of $60 Million Private Placement
18.03.2026

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of $60.0 million to the Company, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about March 19, 2026, subject to satisfaction of customary closing conditions.

Видео

No Data

There is no data to display

Пресс-релизы

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
18.03.2026

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today provided pipeline progress and business updates, including financial results for the fourth quarter and full year ended December 31, 2025. The Company reported favorable topline safety, tolerability and pharmacokinetics (PK) findings from the 7 mg dose cohort of OV329, its next generation GABA-aminotransferase (GABA-AT) inhibitor. Additionally the Company announced it will add complementary development programs for OV329, expanding into tuberous sclerosis complex (TSC) seizures and infantile spasms (IS) which is funded by a private placement financing expected to result in gross proceeds of $60.0 million, before deducting placement agent fees and offering expenses.

Ovid Therapeutics Announces Pricing of $60 Million Private Placement
18.03.2026

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of $60.0 million to the Company, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about March 19, 2026, subject to satisfaction of customary closing conditions.

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
18.12.2025

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

OV350 showed a good safety profile, supporting the advancement of the Company's KCC2 portfolio, including the first oral direct activator, OV4071 There were no treatment-related laboratory findings, no safety findings, and no treatment-related serious adverse events (SAEs) Exploratory quantitative electrophysiology results suggest OV350 had central activity and spectral power consistent with expected physiological effects of KCC2 modulation; aligned with expected drug exposure in the brain Pharmacokinetics for OV350 were as predicted, and will inform dosing strategies for future KCC2 development programs OV4071 (oral) is on track for regulatory submission for a Phase 1/1b clinical trial in Q1 2026 NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by excess neural excitability, today announced results from its Phase 1 study of OV350, the first-ever KCC2 direct activator known to be dosed in humans. The study met its primary objectives to evaluate safety, tolerability and pharmacokinetics.

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
02.12.2025

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid's leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance.